Join
Live feed
·
PRReleasevia Quantisnow
Lexeo Therapeutics Inc. logo

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference

ByQuantisnow·Wall Street's wire, on your screen.
LXEO· Lexeo Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LXEO (Lexeo Therapeutics Inc.) and more on Quantisnow.